Letter

Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment

BMJ 2005; 331 doi: 10.1136/bmj.331.7526.1202 (Published 17 November 2005)
Cite this as: BMJ 2005;331:1202.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Malcolm R Kell (malcolm.kell@breastcheck.ie), consultant surgeon,
  2. Colm P Power
  1. Mater Misericordiae University Hospital, University College Dublin, Republic of Ireland

    EDITOR—The results of recent trials are likely to continue to fuel the demand for trastuzumab in the adjuvant setting of early breast cancer,1 as well as a possible neoadjuvant treatment in the near future. …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular